<code id='7B4C8DF004'></code><style id='7B4C8DF004'></style>
    • <acronym id='7B4C8DF004'></acronym>
      <center id='7B4C8DF004'><center id='7B4C8DF004'><tfoot id='7B4C8DF004'></tfoot></center><abbr id='7B4C8DF004'><dir id='7B4C8DF004'><tfoot id='7B4C8DF004'></tfoot><noframes id='7B4C8DF004'>

    • <optgroup id='7B4C8DF004'><strike id='7B4C8DF004'><sup id='7B4C8DF004'></sup></strike><code id='7B4C8DF004'></code></optgroup>
        1. <b id='7B4C8DF004'><label id='7B4C8DF004'><select id='7B4C8DF004'><dt id='7B4C8DF004'><span id='7B4C8DF004'></span></dt></select></label></b><u id='7B4C8DF004'></u>
          <i id='7B4C8DF004'><strike id='7B4C8DF004'><tt id='7B4C8DF004'><pre id='7B4C8DF004'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          focus

          author:comprehensive    - browse:4466
          Darron Cummings/AP

          Eli Lilly said Friday that it will acquire Dermira, a small biotech developing drugs for chronic skin conditions, for $1.1 billion.

          The centerpiece of the deal is the Dermira drug called lebrikizumab that aims to treat people suffering from moderate-to-severe atopic dermatitis, the most common form of eczema, a disease characterized by inflamed, itchy, and scaly skin.

          advertisement

          Phase 3 clinical trials of lebrikizumab in atopic dermatitis are underway. If successful, the drug could compete against Dupixent, which has grown into a commercial blockbuster for Regeneron Pharmaceuticals and Sanofi.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          entertainment